3.41 USD
▼-0.05-1.45%
盘后 3.63 0.00%
2026-09-15
市值
$308.44M
市盈率
—
EPS
-1.56
股息率
—
52 周区间
1.85 – 5.15
成交量
284.18K
Beta
0.54
目标价
11.64
52W 低 1.8552W 高 5.15
价格走势
公司简介
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.